<DOC>
	<DOCNO>NCT01581398</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Peginterferon alfa-2b ( 40KD , Y shape , following refer Ypeginterferon alfa-2b short ) , dose 180μg/week , combination Ribavirin Chinese chronic hepatitis C patient . The study first group patient two sub-study , genotype 2/3 non-genotype 2/3 , depend HCV genotype infect . In genotype 2/3 sub-study 219 patient enrol , eligible patient randomize 2:1 ratio Ypeginterferon alfa-2b group active control group ( Pegasys ) , receive 24 week interferon therapy oral daily Ribavirin dose 800mg/d . In non-genotype 2/3 sub-study 507 patient enrol , eligible patient randomize 2:1 ratio Ypeginterferon alfa-2b group active control group ( Pegasys ) , receive 48 week interferon therapy oral daily Ribavirin 1000-1200mg/day , base body weight . All patient follow 24 week end therapy .</brief_summary>
	<brief_title>Efficacy Safety Study Peginterferon Alfa-2b Chinese Chronic Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>18~65 year Hepatitis virus C chronic infection evidence : HCV RNA antiHCV positive &gt; 6 month , evidence support diagnosis chronic hepatitis C infection HCV RNA≥2000IU/mL , antiHCV positive screening Pregnancy test female patient must negative . All patient must take effective contraception measure study period Signed inform consent Pregnant lactate woman Mental psychology disorder ANC &lt; 1500/mm3 , PLT &lt; 90,000/mm3 , Hb &lt; ULN ( Upper limit Normal ) Received interferon treatment within previous 6 month show noresponse previous interferon treatment Coinfection HIV , HAV , HBV , HEV Evidence hepatic decompensation ( e.g : Child Plug≥B , prothrombin time prolong 3 second , TBil &gt; 2ULN , Alb &lt; 35g/L ) Hepatocarcinoma suffer malignant tumor Not well control endocrine disease ( e.g : thyroid disfunction , mellitus mellitus ) Significant function damage major organ ( e.g : heart , lung , kidney ) Involved investigation within previous 3 month Other condition opinion investigator preclude enrollment study ( e.g : poor compliance )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Peginterferon</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Sustained virus response</keyword>
	<keyword>HCV</keyword>
</DOC>